Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 25: TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
Author(s): Philipp Lurz Added: 9 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation… View more

Intervention
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin
Author(s): William Herrington Added: 1 year ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,… View more

Cardiovascular Kidney Metabolic
ECG in Severe COVID-19 Infection
Author(s): Kapil Rajendran , Baiju Rajan , Sivaprasad Kunjukrishnapilla , et al Added: 1 year ago

Imaging & Diagnostics

Electrophysiology & Arrhythmia
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 1 year ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Kidney Metabolic
30th Annual Meeting of the ISCP
Author(s): Paula Bouzón Iglesias , Alejandro Gullón de la Roza , Laura Pérez Bacigalupe , et al Added: 1 month ago

Intervention

Prevention & Chronic Conditions
Advancements in Triglyceride-lowering Therapies
Author(s): , Added: 1 year ago
In this video series, recorded at ESC 2024 in London, Prof Gerald Watts (University of Western Australia, Perth, Australia) is joined by Prof Robert S Rosenson (Mount Sinai Icahn School of Medicine, New York, US) to discuss developments in triglyceride-lowering therapies.The faculty consider triglycerides as a risk factor for cardiovascular disease and explore the relationship between… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ESC 24 Hot Line Discussion: The RHEIA Trial
Author(s): Harriette Van Spall , Helene Eltchaninoff Added: 1 year ago
ESC Congress 2024 — Transcatheter aortic valve replacement shows superiority over surgical aortic valve replacement for women with severe aortic stenosis.Host, Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Helene Eltchaninoff (University Hospital of Rouen, FR) to discuss key findings from the RHEIA trial (NCT04160130; Optimapharm).This prospective, randomised study aims to… View more

Demographic

Intervention
TCT 24: The TRISCEND II Trial
Author(s): Susheel Kodali Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more

Intervention
ACC 25: Cardiac Biomarker Analysis from the EARLY TAVR Trial
Author(s): Brian Lindman Added: 1 year ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more

Vascular Disease and Surgery
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic